As filed with the Securities and Exchange Commission on March 11, 2022
Registration
No. 333-
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE
SECURITIES ACT OF 1933
VIRIDIAN THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
Delaware |
|
47-1187261 |
(State or Other Jurisdiction of
Incorporation or Organization) |
|
(I.R.S. Employer
Identification No.) |
Viridian Therapeutics, Inc.
221 Crescent Street, Suite 401
Waltham, MA 02453
(Address of Principal Executive Offices, Zip Code)
Viridian Therapeutics, Inc. 2016 Employee Stock Purchase Plan
Viridian Therapeutics, Inc. 2021 Stock Option Inducement Awards
(Full title of the plans)
Jonathan Violin, Ph.D.
President and Chief Executive Officer
221 Crescent Street, Suite 401
Waltham, MA 02453
(617) 272-4600
(Name, address, including zip code, and telephone number, including area code, of agent
for service)
Copies to:
Sean Feller
Gibson,
Dunn & Crutcher LLP
2029 Century Park East
Los Angeles, CA 90067-3026
(310) 551-8746
Indicate by check mark whether
the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of large accelerated
filer, accelerated filer, smaller reporting company and emerging growth company in Rule 12b-2 of the Exchange Act.
|
|
|
|
|
|
|
Large accelerated filer |
|
☐ |
|
Accelerated filer |
|
☐ |
|
|
|
|
Non-accelerated filer |
|
☒ |
|
Smaller reporting company |
|
☒ |
|
|
|
|
|
|
|
|
Emerging growth company |
|
☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐